Buy & Sell DuPont de Nemours Inc (DD) – DuPont de Nemours Inc Price Today
Aura AI Summary
Key Stats
- $19.73BMarket Cap
- Basic MaterialsSector
- -15.67%3M Drawdown
- $22.19BEnterprise Value
- 1.66%Dividend Yield
- 79 daysTypical Hold Time
DuPont de Nemours Inc (DD) is currently valued at a market capitalization of $19.73B, with an enterprise value of $22.19B. Over the past 52 weeks, DuPont de Nemours Inc has traded between a low of $27.64 and a high of $51.53, highlighting its annual price range. Over the past three months, DuPont de Nemours Inc has recorded a drawdown of -15.67%, reflecting recent price volatility. DuPont de Nemours Inc offers a dividend yield of 1.66%, with the most recent dividend of $0.20 paid on 15 May 26. On average, investors hold DuPont de Nemours Inc for approximately 79 days, indicating typical investor behavior on the platform.
About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Most Recent News
Investigation launched over Regeneron’s optimistic trial claims that preceded stock drop.
Levi & Korsinsky has started an investigation into Regeneron Pharmaceuticals for potentially misleading investors about the results of a clinical trial. In March 2026, Regeneron's investor relations VP expressed hope for positive trial outcomes of a ...

Investigation launched into Prestige Consumer Healthcare over missed earnings and undisclosed acquisition
Levi & Korsinsky has started an investigation into Prestige Consumer Healthcare following the company's failure to meet its Q4 and full-year financial projections, including adjusted gross margin, free cash flow, and adjusted EPS. Additionally, Prest...

Investigation launched into TriSalus Life Sciences after Q1 revenue misses estimates and cuts full-year guidance
Levi & Korsinsky has started an investigation into TriSalus Life Sciences following the company's Q1 2026 revenue of $8.9 million, which missed Wall Street's $9.4 million estimate. The company also lowered its full-year 2026 revenue forecast to $54 m...
